Development and initial validation of the parent acceptable symptom state in juvenile idiopathic arthritis (JIA)

Development and initial validation of the parent acceptable symptom state in juvenile idiopathic arthritis (JIA)

Bibliographic Details
Main Authors:	Filocamo G, Schiappapietra B, Manzoni S Magni, Lanni S, Solari N, Viola S, Pistorio A, Ruperto N, Tani D, Martini A, Ravelli A
Format:	Article
Language:	English
Published:	BMC 2008-09-01
Series:	Pediatric Rheumatology Online Journal

Similar Items

Evaluation of the power of six clustering features in identifying a homogeneous disease subset in juvenile idiopathic arthritis (JIA)
by: Magnani A, et al.
Published: (2008-09-01)

Time of onset of iridocyclitis (IC) in children with juvenile idiopathic arthritis (JIA)
by: Verazza S, et al.
Published: (2008-09-01)

Impact of involvement of individual joint groups on subdimensions of functional ability scales in juvenile idiopathic arthritis
by: Meiorin S, et al.
Published: (2008-09-01)

A meta-analysis to estimate the “real” placebo effect in juvenile idiopathic arthritis (JIA) trials
by: Martini A, et al.
Published: (2011-09-01)

Preliminary validation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 403 clinic patients
by: Solari N, et al.
Published: (2008-09-01)

Agreement between objective and subjective definitions of inactive disease, remission and minimal disease activity in juvenile idiopathic arthritis
by: Davì S, et al.
Published: (2011-09-01)

Comparison of the accuracy of different definitions of clinical remission (CR) and minimal disease activity (MDA) in juvenile idiopathic arthritis (JIA)
by: Davì S, et al.
Published: (2008-09-01)

Final validation of a new composite disease activity score for juvenile idiopathic arthritis: the Juvenile Arthritis Disease Activity Score (JADAS)
by: Consolaro A, et al.
Published: (2008-09-01)

Agreement between physicians and parents in rating functional ability of children with juvenile idiopathic arthritis
by: Buoncompagni Antonella, et al.
Published: (2007-12-01)

Analysis of ceiling effect and score distribution of outcome measures in juvenile idiopathic arthritis (JIA)
by: Lattanzi B, et al.
Published: (2008-09-01)

A new approach to defining inactive disease, minimal disease activity and parent- and child-acceptable symptom state in juvenile idiopathic arthritis
by: Bertamino M, et al.
Published: (2011-09-01)

Talus Arthritis Pattern in Juvenile Idiopathic Arthritis (JIA)
by: Mohammad Alkhreisat MD, et al.
Published: (2019-10-01)

Mandibular condyle destruction in juvenile idiopathic arthritis (JIA)
by: Zak M, et al.
Published: (2008-09-01)

Infliximab to treat chronic uveitis in juvenile idiopathic arthritis (JIA)
by: Bracaglia C, et al.
Published: (2008-09-01)

Juvenile idiopathic arthritis (JIA): can an integrated medicine be possible?
by: Carlomagno R, et al.
Published: (2011-09-01)

Adalimumab and severe uveitis in juvenile idiopathic arthritis (JIA) therapy
by: Alpigiani MG, et al.
Published: (2008-09-01)

Thalidomide: efficacy and side effects in juvenile idiopathic arthritis (JIA)
by: Alpigiani MG, et al.
Published: (2008-09-01)

Replication of the association of the <it>COG6</it> gene with juvenile idiopathic arthritis (JIA)
by: Worthington J, et al.
Published: (2011-09-01)

14.4 Oligoarticular Juvenile Idiopathic Arthritis (JIA): can extension be predicted?
by: Hunter PJ, et al.
Published: (2008-09-01)

Development and initial validation of a new short and simple Health-Related Quality Of Life (HRQL) Questionnaire for Pediatric Rheumatic Diseases (PRD)
by: Palmisani E, et al.
Published: (2008-09-01)

Children with juvenile idiopathic arthritis currently followed in a tertiary care setting have a better psychosocial well-being than healthy peers
by: Suffia C, et al.
Published: (2011-09-01)

Current Treatments for Juvenile Idiopathic Arthritis
by: Alberto eMartini, et al.
Published: (2011-10-01)

Rituximab in ANA positive polyarticular juvenile idiopathic arthritis (JIA) with uveitis
by: Baildam EM, et al.
Published: (2008-09-01)

Do parent's global rating of well-being and disease activity of children with juvenile idiopathic arthritis yield different information?
by: Ullmann N, et al.
Published: (2008-09-01)

How do parents of children with juvenile idiopathic arthritis (JIA) perceive their therapies?
by: Nageswaran Savithri, et al.
Published: (2008-06-01)

Investigating the use of a limited core outcome variable set for the classification of response following methotrexate treatment in juvenile idiopathic arthritis (JIA)
by: Hirani SP, et al.
Published: (2008-09-01)

Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
by: Dehoorne J, et al.
Published: (2011-09-01)

Psychological characteristics of the patients with juvenile idiopathic arthritis (JIA) of various age groups
by: Stepanenko NY
Published: (2011-09-01)

The successes and challenges of harmonising juvenile idiopathic arthritis (JIA) datasets to create a large-scale JIA data resource
by: Saskia Lawson-Tovey, et al.
Published: (2023-07-01)

An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)
by: Bullement A, et al.
Published: (2021-09-01)

Notice of redundant publication: Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
by: Martini Alberto, et al.
Published: (2013-01-01)

Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA)
by: van Pelt Philomien A, et al.
Published: (2012-08-01)

Anakinra in systemic juvenile idiopathic arthritis (soJIA) non responsive to antiTNF
by: Pontikaki I, et al.
Published: (2008-09-01)

Juvenile idiopathic arthritis (JIA) in two tertiary centres in the Western Cape, South Africa
by: Pope Chris, et al.
Published: (2011-09-01)

German evidence- and consensus-based guidelines 2011 for the treatment of juvenile idiopathic arthritis (JIA)
by: Dueckers Gregor, et al.
Published: (2012-07-01)

Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA)
by: Kumar Sharath, et al.
Published: (2012-11-01)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
by: De Benedetti Fabrizio, et al.
Published: (2012-07-01)

Investigating which variables from the core outcome variables in juvenile idiopathic arthritis (JIA) are the best predictors of classification as a responder to treatment with methotrexate (MTX)
by: Hirani SP, et al.
Published: (2008-09-01)

Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care
by: Claire E.H. Barber, et al.
Published: (2019-08-01)

2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)
by: Yokota S, et al.
Published: (2008-09-01)